Phase III Chronic Obstructive Pulmonary Disease Small Molecule Sought
Leiras Takeda Pharmaceuticals Finland flag Finland
Abstract ID:
New prescription drug which will be considered as complimentary product for our roflumilast COPD drug and can be sold to the same target group
Send an Inquiry
RE:
Participants
You

New prescription drug which will be considered as complimentary product for our roflumilast COPD drug and can be sold to the same target group.

Type of Business Relationship Sought

No co-funding or co-development expected from Takeda in Nordics.

FEATURED
Last Updated Jul 2014
Technology Type
Phase of Development CLINICAL TRIALS
CORPORATION

Opportunity Contact